PE20081142A1 - Formulaciones semisolidas de inhibidores de enzima fosfolipasa - Google Patents
Formulaciones semisolidas de inhibidores de enzima fosfolipasaInfo
- Publication number
- PE20081142A1 PE20081142A1 PE2007001496A PE2007001496A PE20081142A1 PE 20081142 A1 PE20081142 A1 PE 20081142A1 PE 2007001496 A PE2007001496 A PE 2007001496A PE 2007001496 A PE2007001496 A PE 2007001496A PE 20081142 A1 PE20081142 A1 PE 20081142A1
- Authority
- PE
- Peru
- Prior art keywords
- alkyl
- enzyme inhibitors
- indol
- pyridinyl
- cycloalkyl
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 2
- ZIIUUSVHCHPIQD-UHFFFAOYSA-N 2,4,6-trimethyl-N-[3-(trifluoromethyl)phenyl]benzenesulfonamide Chemical compound CC1=CC(C)=CC(C)=C1S(=O)(=O)NC1=CC=CC(C(F)(F)F)=C1 ZIIUUSVHCHPIQD-UHFFFAOYSA-N 0.000 title 1
- 102000015439 Phospholipases Human genes 0.000 title 1
- 108010064785 Phospholipases Proteins 0.000 title 1
- 239000002532 enzyme inhibitor Substances 0.000 title 1
- CIUQDSCDWFSTQR-UHFFFAOYSA-N [C]1=CC=CC=C1 Chemical class [C]1=CC=CC=C1 CIUQDSCDWFSTQR-UHFFFAOYSA-N 0.000 abstract 2
- FIULGFJIHJJXMT-UHFFFAOYSA-N [C]1[N]C=CC=C1 Chemical class [C]1[N]C=CC=C1 FIULGFJIHJJXMT-UHFFFAOYSA-N 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- QUPDWYMUPZLYJZ-UHFFFAOYSA-N ethyl Chemical compound C[CH2] QUPDWYMUPZLYJZ-UHFFFAOYSA-N 0.000 abstract 2
- SLRMQYXOBQWXCR-UHFFFAOYSA-N 2154-56-5 Chemical compound [CH2]C1=CC=CC=C1 SLRMQYXOBQWXCR-UHFFFAOYSA-N 0.000 abstract 1
- 239000005711 Benzoic acid Substances 0.000 abstract 1
- WZKSXHQDXQKIQJ-UHFFFAOYSA-N F[C](F)F Chemical group F[C](F)F WZKSXHQDXQKIQJ-UHFFFAOYSA-N 0.000 abstract 1
- -1 PYRIMIDINYL Chemical class 0.000 abstract 1
- 229940124154 Phospholipase inhibitor Drugs 0.000 abstract 1
- 239000002253 acid Substances 0.000 abstract 1
- CZZYITDELCSZES-UHFFFAOYSA-N diphenylmethane Chemical class C=1C=CC=CC=1CC1=CC=CC=C1 CZZYITDELCSZES-UHFFFAOYSA-N 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 229910052736 halogen Inorganic materials 0.000 abstract 1
- 150000002367 halogens Chemical group 0.000 abstract 1
- 230000028709 inflammatory response Effects 0.000 abstract 1
- 230000002452 interceptive effect Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 239000000825 pharmaceutical preparation Substances 0.000 abstract 1
- 239000003428 phospholipase inhibitor Substances 0.000 abstract 1
- 229940124597 therapeutic agent Drugs 0.000 abstract 1
- SXPUVBFQXJHYNS-UHFFFAOYSA-N α-furil Chemical compound C=1C=COC=1C(=O)C(=O)C1=CC=CO1 SXPUVBFQXJHYNS-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Enzymes And Modification Thereof (AREA)
Abstract
SE REFIERE A UNA COMPOSICION DE FORMULA I, DONDE R ES -(CH2)n-A, -(CH2)n-S-A Y -(CH2)n-O-A; A ES i O ii; D ES C1-C6 ALQUILO, C3-C6 CICLOALQUILO, -CF3, -(CH2)1-3-CF3; B Y C SON CADA UNO FENILO, PIRIDINILO, PIRIMIDINILO, FURILO, ENTRE OTROS; n ES 0-3; n1 ES 1-3; n2 ES 0-4, n3 ES 0-4; X1 ES UN ENLACE -S-, -O-, -S(O)-, ENTRE OTROS; R1 ES C1-C6 ALQUILO, C3-C6 CICLOALQUILO TETRAHIDROPIRANILO, ADAMANTILO, ENTRE OTROS; X2 ES -O-, -CH2-, -NH-, ENTRE OTROS; R2 ES UNA PORCION ANULAR DE FENILO, PIRIDINILO, FURILO, TIENILO, ENTRE OTROS; R3 ES HALOGENO, -CN, -CF3, -NH(C1-C6)ALQUILO, ENTRE OTROS; R4 ES H, CN, OH, C1-C6 TIOALQUILO, -NH-C(O)-N(ALQUILO C1-C3)2, ENTRE OTROS; R5 ES H, C1-C3 ALQUILO; R6 ES H C1-C6 ALQUILO. SON COMPUESTOS PREFERIDOS: ACIDO 4-(2-{5-CLORO-1-(DIFENILMETIL)-2-[2-({[2-(TRIFLUOROMETIL)BENCIL]SULFONIL}AMINO)ETIL]-1H-INDOL-3-IL}ETOXI)BENZOICO; ACIDO 4-(3-{1-BENZIHIDROL-5-CLORO-2-[2-(2-METIL-6-NITRO-FENILMETANSULFONILAMINO)ETIL]-1H-INDOL-3-IL}PROPIL)-BENZOICO; ENTRE OTROS. SE REFIERE TAMBIEN A UN PROCEDIMIENTO DE PREPARACION Y COMPOSICIONES FARMACEUTICAS. DICHO COMPUESTO ES UN INHIBIDOR DE FOSFOLIPASAS Y ES UTIL COMO AGENTE TERAPEUTICO POR INTERFERIR EN LA RESPUESTA INFLAMATORIA
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US85557106P | 2006-10-31 | 2006-10-31 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20081142A1 true PE20081142A1 (es) | 2008-09-22 |
Family
ID=39345047
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2007001496A PE20081142A1 (es) | 2006-10-31 | 2007-10-31 | Formulaciones semisolidas de inhibidores de enzima fosfolipasa |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20100093725A1 (es) |
| EP (1) | EP2068829A2 (es) |
| JP (1) | JP2010508304A (es) |
| AR (1) | AR063744A1 (es) |
| AU (1) | AU2007313718A1 (es) |
| BR (1) | BRPI0718042A2 (es) |
| CL (1) | CL2007003146A1 (es) |
| PE (1) | PE20081142A1 (es) |
| TW (1) | TW200826932A (es) |
| WO (1) | WO2008055148A2 (es) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2614144B1 (en) | 2010-09-08 | 2015-07-22 | Twincore Zentrum für Experimentelle und Klinische Infektionsforschung GmbH | Use of inhibitors of phospholipase a2 for the treatment or prevention of flavivirus infection |
| US9487039B2 (en) | 2011-09-09 | 2016-11-08 | Hewlett-Packard Development Company, Lp. | Printer |
| GB201401904D0 (en) | 2014-02-04 | 2014-03-19 | Ziarco Pharma Ltd | Pharmaceutical composition for topical administration |
| CN113941003B (zh) * | 2021-10-25 | 2023-04-28 | 江苏集萃新型药物制剂技术研究所有限公司 | 多聚段组合物、药物制剂及其组合物和制备方法 |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5622832A (en) * | 1990-02-28 | 1997-04-22 | Genetics Institute, Inc. | Arachidonic acid releasing phospholipase A2 enzyme and methods of use |
| US5559158A (en) * | 1993-10-01 | 1996-09-24 | Abbott Laboratories | Pharmaceutical composition |
| US20030104048A1 (en) * | 1999-02-26 | 2003-06-05 | Lipocine, Inc. | Pharmaceutical dosage forms for highly hydrophilic materials |
| US20030235595A1 (en) * | 1999-06-30 | 2003-12-25 | Feng-Jing Chen | Oil-containing, orally administrable pharmaceutical composition for improved delivery of a therapeutic agent |
| US6352718B1 (en) * | 1999-09-27 | 2002-03-05 | American Cyanamid Company | Vasopressin antagonist formulation and process |
| CN1399542A (zh) * | 1999-09-27 | 2003-02-26 | 美国氰胺公司 | 药用载体制剂 |
| US6797708B2 (en) * | 2001-12-03 | 2004-09-28 | Wyeth | Inhibitors of cytosolic phospholipase A2 |
| US7605156B2 (en) * | 2001-12-03 | 2009-10-20 | Wyeth | Methods for the use of inhibitors of cytosolic phospholipase A2 |
| US6984735B2 (en) * | 2001-12-03 | 2006-01-10 | Wyeth | Process for making an aldehyde |
| TW200510305A (en) * | 2003-07-25 | 2005-03-16 | Wyeth Corp | Process for the preparation of CPLA2 inhibitors |
| US7582771B2 (en) * | 2003-09-03 | 2009-09-01 | Wyeth | Process for the synthesis of cPLA2 inhibitors |
| US7342119B2 (en) * | 2003-09-30 | 2008-03-11 | Wyeth Holdings Corporation | Process for the synthesis of a CPLA2 inhibitor |
| WO2005049566A1 (en) * | 2003-11-17 | 2005-06-02 | Wyeth | Processes for the preparation of n-substituted phthalimides |
| HN2004000536A (es) * | 2003-12-16 | 2009-02-18 | Wyeth Corp | Un procediemiento de sintesis para la alquilacion reductiva de la posicon c-3 de indoles |
| AR048239A1 (es) * | 2004-02-25 | 2006-04-12 | Wyeth Corp | Procesos para la preparacion de haluros de aril- y heteroaril-alquilsulfonilo e intermediarios de sintesis de los mismos |
| PA8626701A1 (es) * | 2004-03-26 | 2006-05-16 | Wyeth Corp | Procedimientos para la preparacion de compuestos aminoarilos yodados |
| US20050244367A1 (en) * | 2004-05-03 | 2005-11-03 | Ilypsa, Inc. | Phospholipase inhibitors localized in the gastrointestinal lumen |
| AR053410A1 (es) * | 2004-08-19 | 2007-05-09 | Wyeth Corp | Proceso para la sintesis de indoles n-alquilados c-2, c-3 sustituidos. compuestos intermediarios |
| TW200718687A (en) * | 2005-05-27 | 2007-05-16 | Wyeth Corp | Inhibitors of cytosolic phospholipase A2 |
-
2007
- 2007-10-30 WO PCT/US2007/082985 patent/WO2008055148A2/en not_active Ceased
- 2007-10-30 CL CL2007003146A patent/CL2007003146A1/es unknown
- 2007-10-30 JP JP2009534939A patent/JP2010508304A/ja not_active Withdrawn
- 2007-10-30 BR BRPI0718042-0A patent/BRPI0718042A2/pt not_active Application Discontinuation
- 2007-10-30 US US12/513,101 patent/US20100093725A1/en not_active Abandoned
- 2007-10-30 AU AU2007313718A patent/AU2007313718A1/en not_active Abandoned
- 2007-10-30 TW TW096140778A patent/TW200826932A/zh unknown
- 2007-10-30 EP EP07868619A patent/EP2068829A2/en not_active Withdrawn
- 2007-10-31 AR ARP070104830A patent/AR063744A1/es unknown
- 2007-10-31 PE PE2007001496A patent/PE20081142A1/es not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| TW200826932A (en) | 2008-07-01 |
| WO2008055148A2 (en) | 2008-05-08 |
| US20100093725A1 (en) | 2010-04-15 |
| AU2007313718A1 (en) | 2008-05-08 |
| CL2007003146A1 (es) | 2008-01-25 |
| BRPI0718042A2 (pt) | 2013-11-12 |
| JP2010508304A (ja) | 2010-03-18 |
| WO2008055148A3 (en) | 2008-11-06 |
| AR063744A1 (es) | 2009-02-18 |
| EP2068829A2 (en) | 2009-06-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20090815A1 (es) | Compuesto de amida | |
| PE20090903A1 (es) | Derivados de acido azabifenilaminobenzoico como inhibidores de la dihidroorotato deshidrogenasa | |
| PE20080835A1 (es) | Derivados novedosos de aminopiridina que tienen accion inhibidora selectiva sobre aurora a | |
| PE20070593A1 (es) | Compuestos pirrolopirimidina como inhibidores de syk | |
| PE20020354A1 (es) | Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda) | |
| PE20060243A1 (es) | Derivados de 4-amino insustituido-5-(4-urea-fenil)-pirrolotriazina | |
| PE20090694A1 (es) | Compuestos moduladores de sirtuinas | |
| RU2409562C2 (ru) | Новые производные 2-азетидинона в качестве ингибиторов всасывания холестерина для лечения гиперлипидемических состояний | |
| PE20091682A1 (es) | Compuestos de carbamoilo como inhibidores de dgat1 190 | |
| PE20141700A1 (es) | Compuestos de 2-(2,4,5-anilino sustituido) pirimidina | |
| PE20110285A1 (es) | Derivados de sulfonamidofenil propionamida como ligandos del receptor vaniloide del subtipo 1 | |
| PE20050018A1 (es) | Compuesto pentaciclico heteroaromatico como inhibidor de la proteina tirosina fosfatasa 1b (ptb1b) | |
| AR072490A1 (es) | 1,2,5- oxadiazoles como inhibidores de indolamina 2,3 dioxigenasa | |
| PE20060525A1 (es) | Compuestos heterociclicos como inhibidores de cetp | |
| PE20080906A1 (es) | Derivados heteroarilo como inhibidores de citocina | |
| PE20091065A1 (es) | Derivados bis-(sulfonilamino) en terapia 066 | |
| PE20040155A1 (es) | Derivados aminoinazoles, procedimiento de preparacion e intermedios de este procedimiento a titulo de medicamentos y composiciones farmaceuticas que los contienen | |
| PE20061305A1 (es) | Compuestos derivados de fenilacetamidas como inhibidores de proteincinasas | |
| PE20050991A1 (es) | Derivados de benceno sulfonamida | |
| PE20061490A1 (es) | Derivados de ciclohexanosulfonilo como inhibidores del transportador de glicina glyt1 | |
| PE20121050A1 (es) | Compuestos de n-(1-(4-(1h-pirazol-5-il)ftalazin-1-il)piperidin-4-il)-benzamida sustituidos como antagonistas de la trayectoria hedgehog | |
| PE20090601A1 (es) | Derivados de piridin-il-oxi-piridinas como inhibidores de alk5 | |
| ATE277889T1 (de) | Aminobenzophenone als inhibitoren von il-1beta und tnf-alpha | |
| PE20091243A1 (es) | Compuesto heterociclico fusionado | |
| PE20030925A1 (es) | Esteres hidroxamato de acido n-(4-fenil-sustituido)-antranilico |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |